Verdad Biotech Fund, L.P.

The absence of prior EDGAR filings from this manager indicates this is a debut institutional fund vehicle, suggesting Rasmussen is either transitioning from a different operating entity (family office, earlier fund without EDGAR obligations, or industry role) or launching a first formal commingled biotech hedge strategy.

The mid-2026 filing timing aligns with sustained biotech sector volatility and potential repricing of public biotech equities and private company valuations, creating both opportunity in secondary positions and pressure to deploy capital before LP appetite shifts further toward late-stage or infrastructure allocations.

Before commitment, verify whether Rasmussen has prior fund management experience outside EDGAR's coverage (non-hedge fund vehicles, smaller exempt offerings, or advisory roles) and confirm the fund's key-man clause terms, as a single-GP debut vehicle with no institutional track record on file creates heightened key-person risk.